FDA panel splits on significance of Optimer's (OPTR) fidaxomicin relapse data
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Join SI Premium – FREE
FDA panel splits on significance of Optimer's (Nasdaq: OPTR) fidaxomicin relapse data
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
